SPY417.26+1.39 0.33%
DIA341.86+1.53 0.45%
IXIC14,052.34+13.58 0.10%

BRIEF-Galmed Pharmaceuticals Announces Dosing Of First Subject In First Human Phase 1 Trial Of Amilo-5Mer

· 03/16/2021 08:57
BRIEF-Galmed Pharmaceuticals Announces Dosing Of First Subject In First Human Phase 1 Trial Of Amilo-5Mer

- Galmed Pharmaceuticals Ltd GLMD.O:

  • GALMED PHARMACEUTICALS ANNOUNCES DOSING OF FIRST SUBJECT IN FIRST IN HUMAN PHASE 1 TRIAL OF AMILO-5MER

Source text for Eikon: ID:nPn6cZwbXa

Further company coverage: GLMD.O


((Reuters.Briefs@thomsonreuters.com;))